PRO-PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE I TRIAL OF DAVANAT/5-FU IN REFRACTORY CANCER PATIENTS

Pro-Pharmaceuticals, a developer of novel carbohydrate compounds that enable the targeted delivery of chemotherapy drugs to cancer cells, has completed the enrollment of patients in its Phase I clinical trial to evaluate Davanat alone and in combination with the chemotherapeutic drug 5-Fluorouracil in refractory patients with solid tumors.

With enrollment closed, the company is focused on finishing the treatment and evaluation of patients in the trial.